Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

COFFEE MICHAEL DENIS

2. Date of Event Requiring Statement (MM/DD/YYYY) 4/9/2014

3. Issuer Name and Ticker or Trading Symbol

Adamas Pharmaceuticals Inc [ADMS]

(Last) (First) (Middle)

C/O ADAMAS PHARMACEUTICALS, INC., 2200 POWELL ST, STE 220

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below)
Senior VP, Strategy & Planning /

(Street)

EMERYVILLE, CA 94608

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽¹⁾	9/30/2019	Common Stock	36666	$1.755	D
Stock Option (Right to Buy)	⁽²⁾	11/16/2021	Common Stock	20000	$0.665	D
Stock Option (Right to Buy)	⁽³⁾	2/22/2022	Common Stock	8750	$0.665	D
Stock Option (Right to Buy)	⁽⁴⁾	12/13/2023	Common Stock	110000	$3.305	D

Explanation of Responses:
( 1)	The Option shares shall vest as follows: one-fourth (1/4th) of the shares vest one year after May 11, 2009; the balance of the shares vest in a series of forty-eight (48) successive equal monthly installments measured from the first anniversary of May 11, 2009, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2007 Stock Plan) as of each such date. The Option shares are subject to an early exercise right and may be exercised in full prior to vesting.
( 2)	The Option shares shall vest as follows: 1/8th of the shares subject to such option shall vest each month after May 30, 2011, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2007 Stock Plan) as of each such date. The Option shares are subject to an early exercise right and may be exercised in full prior to vesting.
( 3)	The Option shares shall vest as follows: 1/8th of the shares subject to such option shall vest on the last day of each fiscal quarter after March 1, 2012, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2007 Stock Plan) as of each such date. The Option shares are subject to an early exercise right and may be exercised in full prior to vesting.
( 4)	The Option shares shall vest as follows: one-fifth (1/5th) of the shares vest one year after November 27, 2013; the balance of the shares vest in a series of forty-eight (48) successive equal monthly installments measured from the first anniversary of November 27, 2013, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2007 Stock Plan) as of each such date. The Option shares are subject to an early exercise right and may be exercised in full prior to vesting.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
COFFEE MICHAEL DENIS C/O ADAMAS PHARMACEUTICALS, INC. 2200 POWELL ST, STE 220 EMERYVILLE, CA 94608			Senior VP, Strategy & Planning

Signatures
/s/Danielle Naftulin, Attorney-in-Fact		4/10/2014
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.